From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q1 2024 call → NOWe need to determine if management describes a recent crossing into an approved/specified/listed/qualified status within buyers' systems, such that future business can arrive without discrete selling events, and that this is new enough that most volume is still ahead. Scan the transcript for relevant statements. Management discusses strategic initiatives: energy storage (Eos), desalination for beneficial reuse, Arkansas bromine, lithium JV with ExxonMobil. They mention progress on these initiatives. For example, on Eos: "we remain in close contact with Eos are very encouraged with the progress they're making on automating their first production line. We fully expect Eos to be up and running their Z3 zinc bromine battery automation line in the second half of this year, which is expected to result material sales of electrolyte from TETRA." That's about a customer's automation, not about TETRA being placed into a buyer's system. On desalination: "we're hopeful to have our first commercial desalination for beneficial reuse contract in place that should be operational by the first part of 2025." That's a contract, not a listing or qualification. On bromine: "By the end of June, we hope to publish our Arkansas Bromine Definitive Feasibility Report... with financing in place for bromine, we expect Board approval to move forward with this project." That's about project approval, not buyer-side access. On lithium: "we continue advancing the FEED study... finalizing negotiations for the joint venture... We continue to work with ExxonMobil on many fronts to advance our project." That's about a JV, not about being placed into a purchasing system. The question asks specifically about the company having recently crossed into being an approved, specified, listed, qualified, registered, reimbursed, or pre-authorized choice inside buyers' own systems. The transcript does not mention any such status. There is no mention of being added to a supplier list, being written into specifications, being qualified onto a roster, etc. The only mentions are about contracts, projects, and partnerships, but those are ordinary selling relationships or project developments, not a systemic access change. Also, the question requires that management conveys that this status is recent and that most volume is still ahead. Even if there were such a status, it's not described.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.